Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

TBK1 Limits mTORC1 by Promoting Phosphorylation of Raptor Ser877.

Antonia RJ, Castillo J, Herring LE, Serafin DS, Liu P, Graves LM, Baldwin AS, Hagan RS.

Sci Rep. 2019 Sep 17;9(1):13470. doi: 10.1038/s41598-019-49707-8.

2.

Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.

Da C, Zhang D, Stashko M, Vasileiadi E, Parker RE, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, Earp HS, Graham DK, Frye SV, Wang X, Kireev D.

J Am Chem Soc. 2019 Oct 2;141(39):15700-15709. doi: 10.1021/jacs.9b08660. Epub 2019 Sep 20.

PMID:
31497954
3.

Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells.

Kuciauskas D, Dreize N, Ger M, Kaupinis A, Zemaitis K, Stankevicius V, Suziedelis K, Cicenas J, Graves LM, Valius M.

Cancers (Basel). 2019 Jul 11;11(7). pii: E972. doi: 10.3390/cancers11070972.

4.

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.

Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, Huang D, Whiten GC, Larson JE, Wang X, Pearce KH, Herring LE, Graves LM, Frye SV, Emanuele MJ, Cox AD, Der CJ.

Sci Signal. 2019 Jul 16;12(590). pii: eaav7259. doi: 10.1126/scisignal.aav7259.

5.

Pathway-Based High-Throughput Chemical Screen Identifies Compounds That Decouple Heterochromatin Transformations.

MacDonald IA, Butler KV, Herring LE, Clinkscales SE, Yelagandula R, Stecher K, Bell O, Graves LM, Jin J, Hathaway NA.

SLAS Discov. 2019 Sep;24(8):802-816. doi: 10.1177/2472555219849838. Epub 2019 May 30.

PMID:
31145866
6.

Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.

Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, Herring LE, Gilbert TSK, East MP, McDonald IM, Lockett MR, Ashamalla H, Moorman NJ, Karanewsky DS, Iwanowicz EJ, Holmuhamedov E, Graves LM.

ACS Chem Biol. 2019 May 17;14(5):1020-1029. doi: 10.1021/acschembio.9b00222. Epub 2019 May 1.

7.

Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma.

Cann ML, Herring LE, Haar LL, Gilbert TSK, Goldfarb D, Richards KL, Graves LM, Lawrence DS.

J Proteome Res. 2019 Jan 4;18(1):522-534. doi: 10.1021/acs.jproteome.8b00841. Epub 2018 Dec 21.

PMID:
30540191
8.

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.

Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ.

Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001.

9.

Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth.

Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, Baines AT, Graves LM.

SLAS Discov. 2018 Sep;23(8):850-861. doi: 10.1177/2472555218773045. Epub 2018 May 9.

10.

Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer.

Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM.

Oncotarget. 2018 Jan 29;9(21):15480-15497. doi: 10.18632/oncotarget.24337. eCollection 2018 Mar 20.

11.

My possessions need me: Anthropomorphism and hoarding.

Burgess AM, Graves LM, Frost RO.

Scand J Psychol. 2018 Jun;59(3):340-348. doi: 10.1111/sjop.12441. Epub 2018 Apr 2.

PMID:
29608213
12.

Chronic E-Cigarette Exposure Alters the Human Bronchial Epithelial Proteome.

Ghosh A, Coakley RC, Mascenik T, Rowell TR, Davis ES, Rogers K, Webster MJ, Dang H, Herring LE, Sassano MF, Livraghi-Butrico A, Van Buren SK, Graves LM, Herman MA, Randell SH, Alexis NE, Tarran R.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):67-76. doi: 10.1164/rccm.201710-2033OC.

13.

p32 regulates ER stress and lipid homeostasis by down-regulating GCS1 expression.

Liu Y, Leslie PL, Jin A, Itahana K, Graves LM, Zhang Y.

FASEB J. 2018 Jul;32(7):3892-3902. doi: 10.1096/fj.201701004RR. Epub 2018 Feb 20.

14.

Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.

Asquith CRM, Laitinen T, Bennett JM, Godoi PH, East MP, Tizzard GJ, Graves LM, Johnson GL, Dornsife RE, Wells CI, Elkins JM, Willson TM, Zuercher WJ.

ChemMedChem. 2018 Jan 8;13(1):48-66. doi: 10.1002/cmdc.201700663. Epub 2017 Nov 27.

15.

Data on peptides identified by mass spectrometry analysis of in vitro DYRK1A-mediated phosphorylation sites on GLI1.

Ehe BK, Lamson DR, Tarpley M, Onyenwoke RU, Graves LM, Williams KP.

Data Brief. 2017 Oct 2;15:577-583. doi: 10.1016/j.dib.2017.09.057. eCollection 2017 Dec.

16.

Identification of a DYRK1A-mediated phosphorylation site within the nuclear localization sequence of the hedgehog transcription factor GLI1.

Ehe BK, Lamson DR, Tarpley M, Onyenwoke RU, Graves LM, Williams KP.

Biochem Biophys Res Commun. 2017 Sep 23;491(3):767-772. doi: 10.1016/j.bbrc.2017.07.107. Epub 2017 Jul 20.

17.

p32 heterozygosity protects against age- and diet-induced obesity by increasing energy expenditure.

Liu Y, Leslie PL, Jin A, Itahana K, Graves LM, Zhang Y.

Sci Rep. 2017 Jul 18;7(1):5754. doi: 10.1038/s41598-017-06209-9.

18.

Ionizing radiation induces EphA2 S897 phosphorylation in a MEK/ERK/RSK-dependent manner.

Graves PR, Din SU, Ashamalla M, Ashamalla H, Gilbert TSK, Graves LM.

Int J Radiat Biol. 2017 Sep;93(9):929-936. doi: 10.1080/09553002.2017.1355580.

PMID:
28705041
19.

BIRC6 mediates imatinib resistance independently of Mcl-1.

Okumu DO, East MP, Levine M, Herring LE, Zhang R, Gilbert TSK, Litchfield DW, Zhang Y, Graves LM.

PLoS One. 2017 May 16;12(5):e0177871. doi: 10.1371/journal.pone.0177871. eCollection 2017.

20.

Measuring Kinase Activity-A Global Challenge.

Cann ML, McDonald IM, East MP, Johnson GL, Graves LM.

J Cell Biochem. 2017 Nov;118(11):3595-3606. doi: 10.1002/jcb.26103. Epub 2017 May 31. Review.

PMID:
28464261
21.

Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.

Stratford JK, Yan F, Hill RA, Major MB, Graves LM, Der CJ, Yeh JJ.

PLoS One. 2017 Apr 5;12(4):e0174863. doi: 10.1371/journal.pone.0174863. eCollection 2017.

22.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

23.

Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals.

Arend KC, Lenarcic EM, Vincent HA, Rashid N, Lazear E, McDonald IM, Gilbert TS, East MP, Herring LE, Johnson GL, Graves LM, Moorman NJ.

Mol Cell Proteomics. 2017 Apr;16(4 suppl 1):S263-S276. doi: 10.1074/mcp.M116.065375. Epub 2017 Feb 25.

24.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.

25.

Probing the global kinome and phosphoproteome in Chlamydomonas reinhardtii via sequential enrichment and quantitative proteomics.

Werth EG, McConnell EW, Gilbert TS, Couso Lianez I, Perez CA, Manley CK, Graves LM, Umen JG, Hicks LM.

Plant J. 2017 Jan;89(2):416-426. doi: 10.1111/tpj.13384. Epub 2017 Jan 17.

26.

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL.

Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9.

27.

CHCHD2 inhibits apoptosis by interacting with Bcl-x L to regulate Bax activation.

Liu Y, Clegg HV, Leslie PL, Di J, Tollini LA, He Y, Kim TH, Jin A, Graves LM, Zheng J, Zhang Y.

Cell Death Differ. 2015 Jun;22(6):1035-46. doi: 10.1038/cdd.2014.194. Epub 2014 Dec 5.

28.

Assessing adaptation of the cancer kinome in response to targeted therapies.

Zawistowski JS, Graves LM, Johnson GL.

Biochem Soc Trans. 2014 Aug;42(4):765-9. doi: 10.1042/BST20130274. Review.

29.

Recipe for growing healthy children: child care culinary workshops lead to improved menus, mealtime environments, and nutrition education.

Mayfield BJ, Graves LM.

J Nutr Educ Behav. 2014 Nov-Dec;46(6):627-8. doi: 10.1016/j.jneb.2014.05.009. Epub 2014 Jul 4. No abstract available.

PMID:
24998175
30.

Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation.

Liu Y, He Y, Jin A, Tikunov AP, Zhou L, Tollini LA, Leslie P, Kim TH, Li LO, Coleman RA, Gu Z, Chen YQ, Macdonald JM, Graves LM, Zhang Y.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):E2414-22. doi: 10.1073/pnas.1315605111. Epub 2014 May 28.

31.

Population structure of Listeria monocytogenes serotype 4b isolates from sporadic human listeriosis cases in the United States from 2003 to 2008.

Lee S, Ward TJ, Graves LM, Tarr CL, Siletzky RM, Kathariou S.

Appl Environ Microbiol. 2014 Jun;80(12):3632-44.

32.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

33.

An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation.

Turowec JP, Zukowski SA, Knight JD, Smalley DM, Graves LM, Johnson GL, Li SS, Lajoie GA, Litchfield DW.

Mol Cell Proteomics. 2014 May;13(5):1184-97. doi: 10.1074/mcp.M113.037374. Epub 2014 Feb 20.

34.

The splicing activator DAZAP1 integrates splicing control into MEK/Erk-regulated cell proliferation and migration.

Choudhury R, Roy SG, Tsai YS, Tripathy A, Graves LM, Wang Z.

Nat Commun. 2014;5:3078. doi: 10.1038/ncomms4078.

35.

Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.

Beltran AS, Graves LM, Blancafort P.

Oncogene. 2014 Sep 25;33(39):4767-77. doi: 10.1038/onc.2013.422. Epub 2013 Oct 21.

36.

Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.

Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, Johnson GL, Baldwin AS, Graves LM.

PLoS One. 2013 Jun 24;8(6):e66755. doi: 10.1371/journal.pone.0066755. Print 2013.

37.

Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.

Fiordalisi JJ, Dewar BJ, Graves LM, Madigan JP, Cox AD.

PLoS One. 2013 May 17;8(5):e64309. doi: 10.1371/journal.pone.0064309. Print 2013.

38.

Hsp90 Inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells.

Che Y, Best OG, Zhong L, Kaufman KL, Mactier S, Raftery M, Graves LM, Mulligan SP, Christopherson RI.

J Proteome Res. 2013 Apr 5;12(4):1710-22. doi: 10.1021/pr301055y. Epub 2013 Mar 22.

PMID:
23458665
39.

Genetic determinants for cadmium and arsenic resistance among Listeria monocytogenes serotype 4b isolates from sporadic human listeriosis patients.

Lee S, Rakic-Martinez M, Graves LM, Ward TJ, Siletzky RM, Kathariou S.

Appl Environ Microbiol. 2013 Apr;79(7):2471-6. doi: 10.1128/AEM.03551-12. Epub 2013 Feb 1.

40.

The dynamic nature of the kinome.

Graves LM, Duncan JS, Whittle MC, Johnson GL.

Biochem J. 2013 Feb 15;450(1):1-8. doi: 10.1042/BJ20121456. Review.

41.

Listeriosis outbreaks and associated food vehicles, United States, 1998-2008.

Cartwright EJ, Jackson KA, Johnson SD, Graves LM, Silk BJ, Mahon BE.

Emerg Infect Dis. 2013 Jan;19(1):1-9; quiz 184. doi: 10.3201/eid1901.120393.

42.

Invasive listeriosis in the Foodborne Diseases Active Surveillance Network (FoodNet), 2004-2009: further targeted prevention needed for higher-risk groups.

Silk BJ, Date KA, Jackson KA, Pouillot R, Holt KG, Graves LM, Ong KL, Hurd S, Meyer R, Marcus R, Shiferaw B, Norton DM, Medus C, Zansky SM, Cronquist AB, Henao OL, Jones TF, Vugia DJ, Farley MM, Mahon BE.

Clin Infect Dis. 2012 Jun;54 Suppl 5:S396-404. doi: 10.1093/cid/cis268.

PMID:
22572660
43.

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL.

Cell. 2012 Apr 13;149(2):307-21. doi: 10.1016/j.cell.2012.02.053.

44.

Defining the expressed breast cancer kinome.

Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS 3rd, Graves LM, Gomez SM, Johnson GL.

Cell Res. 2012 Apr;22(4):620-3. doi: 10.1038/cr.2012.25. Epub 2012 Feb 7. No abstract available.

45.

RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.

Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J, Miller CR, Vigil D, Graves LM, Der CJ.

Small GTPases. 2011 Jul;2(4):202-210. Epub 2011 Jul 1.

46.

Atypical Listeria monocytogenes serotype 4b strains harboring a lineage II-specific gene cassette.

Lee S, Ward TJ, Graves LM, Wolf LA, Sperry K, Siletzky RM, Kathariou S.

Appl Environ Microbiol. 2012 Feb;78(3):660-7. doi: 10.1128/AEM.06378-11. Epub 2011 Dec 2.

47.

Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.

Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, Zimmerman E, Graves LM, Blancafort P.

Breast Cancer Res. 2011 Sep 27;13(5):R94. doi: 10.1186/bcr3019.

48.

Glucose regulates clathrin adaptors at the trans-Golgi network and endosomes.

Aoh QL, Graves LM, Duncan MC.

Mol Biol Cell. 2011 Oct;22(19):3671-83. doi: 10.1091/mbc.E11-04-0309. Epub 2011 Aug 10.

49.

"Going KiNativ": probing the Native Kinome.

Graves LM, Litchfield DW.

Chem Biol. 2011 Jun 24;18(6):683-4. doi: 10.1016/j.chembiol.2011.06.001.

50.

A biosensor generated via high-throughput screening quantifies cell edge Src dynamics.

Gulyani A, Vitriol E, Allen R, Wu J, Gremyachinskiy D, Lewis S, Dewar B, Graves LM, Kay BK, Kuhlman B, Elston T, Hahn KM.

Nat Chem Biol. 2011 Jun 12;7(7):437-44. doi: 10.1038/nchembio.585. Erratum in: Nat Chem Biol. 2012 Aug;8(8):737.

Supplemental Content

Loading ...
Support Center